CITY OF BRISBANE, Calif. – BRISBANE, Calif. (AP) _ Aimmune Therapeutics Inc. (AIMT) on Thursday reported a loss of $16 million in its fourth quarter.
On a per-share basis, the Brisbane, California-based company said it had a loss of 39 cents.
The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 31 cents per share.
For the year, the company reported profit of $35.8 million, or $1.88 per share.
Aimmune Therapeutics shares have fallen slightly more than 3 per cent since the beginning of the year.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AIMT at http://www.zacks.com/ap/AIMT
Keywords: Aimmune Therapeutics, Earnings Report